Quality of Life in Patients with Psoriasis: A Systematic Literature Review  by de Korte, John et al.
Quality of Life in Patients with Psoriasis: A Systematic
Literature Review
John de Korte, Mirjam A. G. Sprangers, Femke M. C. Mombers, and Jan D. Bos
Departments of Dermatology and Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
Data on physical, psychological, and social functioning of patients with psoriasis have been presented in many
studies. The introduction of quality-of-life questionnaires has made it possible to systematically compare these
data across studies. The aim of this study was to present an overview of quality-of-life data and to describe the
relationship between demographic and clinical variables and quality of life in patients with psoriasis. Computerized
bibliographic databases were screened for publications from January 1966 to April 2000. Predeﬁned selection
criteria were used to identify quality-of-life studies in psoriasis. Two investigators independently assessed and,
subsequently, agreed on inclusion. Data were extracted on the objectives, methods, sample characteristics, and
results of the studies. A total of 118 publications were found. Seventeen studies met the inclusion criteria. Patients
with psoriasis reported physical discomfort, impaired emotional functioning, a negative body and self-image, and
limitations in daily activities, social contacts and (skin-exposing) activities, and work. More severe psoriasis was
associated with lower levels of quality of life. There was a tendency that higher age was associated with slightly
lower levels of physical functioning and slightly higher levels of psychological functioning and overall quality of
life. Sex and quality of life were found to be unrelated.
J Investig Dermatol Symp Proc 9:140 –147, 2004
Health-related quality of life reflects patients’ subjective
evaluation of the impact of disease and/or treatment on
their physical, psychological, and social functioning and
well-being. It is a comprehensive construct, especially
relevant in the study and management of diseases affecting
patients’ daily lives (Fitzpatrick et al, 1992; Guyatt et al,
1993; Essink-Bot and de Haes, 1996; Testa and Simonson,
1996; Doward and McKenna, 1998). Health care in chronic
disease is increasingly directed toward both a decrease of
physical symptoms and an increase of quality of life. The
number of outcome studies that include quality-of-life
assessment is rapidly growing (Faust, 1998; Finlay, 1994;
Kurwa and Finlay, 1995; Marks, 1996; McKenna and Stern,
1996; Fleischer et al, 1997; Wall et al, 1998; Gupta et al,
1999;).
Psoriasis is a chronic skin disease affecting physical,
psychological, and social functioning. Dermatologic treat-
ment of psoriasis has become increasingly effective, but—
until now—can only result in a temporary remission of
physical symptoms. A challenge to the patients is therefore
to cope with psoriasis in everyday life. A challenge to
dermatologic care is to realize long-lasting remittance of
physical symptoms as well as a substantial improvement of
quality of life.
For many years, studies have been published on the
psychological and social aspects of psoriasis (Wittkower,
1946; Susskind and McGuire, 1959; Goldsmith et al, 1969;
Baughman and Sobel, 1971; Coles, 1975; Stankler, 1981;
Matussek et al, 1985; Gupta et al, 1987; Ramsay and
O’Reagan, 1988) Nevertheless, it is only for about a decade
that these studies have become more uniform in their
research methodology. This uniformity is particularly in-
creased by the development and use of quality-of-life
questionnaires. Application of these questionnaires enables
comparisons of quality-of-life data across patients with
psoriasis, as well as comparisons with data of patients with
other (skin) diseases and the general population.
The aim of this study is to present an overview of the
quality of life of patients with psoriasis as reported with
these questionnaires. Additionally, data will be presented on
the relationship between demographic and clinical variables
and quality of life.
Results
A total of 118 publications were extracted. Seventeen
studies met the inclusion criteria (Finlay, 1994; Finlay et al,
1990; Root et al, 1994; Finlay and Coles, 1995; Gupta and
Gupta, 1995; Kurwa and Finlay, 1995; Koo, 1996; Nichol
et al, 1996; O’Neill and Kelly, 1996; Fleischer et al, 1997;
Fortune et al, 1997; McKenna and Stern, 1997; Wall et al,
1998; Gupta et al, 1999; Rapp et al, 1999; Wahl et al, 1999a,
b; these studies are represented in the tables by Arabic
numerals 1–17). The primary objectives of these studies
were to describe quality of life; to test the psychometric
Abbreviations: DLQI, Dermatology Life Quality Index; PDI, Psor-
iasis Disability Index; SF-36, MOS 36-Item Short-Form Health
Survey; SIP, Sickness Impact Profile.
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performance of quality-of-life questionnaires; to examine
the relation between demographic, clinical, and/or psycho-
logical variables and quality of life; and to determine the
efficacy of dermatologic treatment. The variability between
the studies was large with respect to study design, sample
characteristics, disease severity, and measures (Table I).
Twelve studies were cross-sectional. In these studies
quality of life was assessed before, during, or after
treatment. In the longitudinal, outcome studies quality of
life was assessed before and after treatment or during
follow-up. Two population-based studies included patients
not undergoing treatment. The sample size of the studies
ranged from 20 to 877 patients, the male:female ratio from
80:20 to 41:59, and the mean age from 43 to 56 y. Disease
severity ranged from clear to severe. Quality of life was
measured by means of 14 different questionnaires: six
generic, applicable to all diseases, and eight disease-
specific. Of these, three generic and five disease-specific
questionnaires assessed concepts related but not identical
to quality of life, such as disability, stress, and distress.
Quality of life
Overall quality of life The overall scores of four question-
naires were presented in more than one study, thereby
enabling comparisons across studies: the DLQI, the PDI,
the SF-36, and the SIP. The mean overall DLQI scores were
23.4 and 46.3, and the mean overall PDI scores ranged from
16.5 to 44, both on a scale from 0 (no disability) to 100
(maximum disability). DLQI and PDI scores can be
compared with each other, and DLQI-scores with scores
of patients with other skin diseases (Finlay, 1998). Never-
theless, the absence of formal reference values or norm
scores, and the variability of the scores, preclude a
straightforward interpretation. A relationship with disease-
severity scores could neither be determined.
The mean overall SF-36 scores, represented by a
physical component summary score and a mental compo-
nent summary score, ranged from 41.2 to 55.5 and 45.2 to
50.9, respectively (Table II). A score of 50 reflects an
average quality of life in the general population. Physical
quality of life in patients with psoriasis was significantly
lower than that of the general population in two studies and
significantly higher than that in another two studies. Mental
quality of life in patients with psoriasis was significantly
lower than that of the general population in three studies
and significantly higher than that in one study. The mean
overall SIP scores, ranged from 8.9 to 10.2. Although formal
comparisons with population norms were not made, these
scores indicate a lower level of quality of life in patients with
psoriasis than in that of the general population (Rodin and
Voshart, 1987; Jacobs et al, 1990).
Physical functioning The assessment of physical function-
ing encompassed issues such as physical symptoms,
physical functioning and/or mobility, daily activities, vitality,
and sleep and rest (Table III). Physical symptoms or
complaints most frequently reported were itching, scaling,
and/or pain. Physical functioning and/or mobility, covering
activities such as walking, carrying, climbing stairs, and
daily work, were found to be impaired. Specific daily
activities affected by psoriasis were home management
(problems with work around the house or garden), clothing
(having to wear special clothes and/or having to change or
wash clothes more often), and bathing (having to take more
baths than usual). Finally, both vitality (energy, vigor, and
absence of fatigue) and sleep and rest (sleeping, sitting,
and napping during the day) were found to be adversely
affected.
Psychological functioning The assessment of psychological
functioning encompassed issues such as general mental
health, emotions, body, and self-image and psoriasis-
related concern (Table III). Patients reported impaired
general mental health (anxiety, depression, loss of beha-
vioral or emotional control, and psychological well-being)
and a wide range of emotional reactions, such as shame,
embarrassment, self-consciousness, anxiety, anger, help-
lessness, and depression. Negative effects of psoriasis
on body and self-image (feeling unclean, feeling physically
unattractive and/or sexually undesirable, and adverse
effects on physical appearance, self-esteem, and self-
confidence) were reported. Finally, patients reported ‘‘pre-
occupation with psoriasis’’ and with ‘‘worries or concern
about psoriasis.’’
Social functioning The assessment of social functioning
encompassed issues such as social contacts and activities,
skin-exposing social activities, sports, sexual behavior,
hairdressing, personal relationships, and work and career
(Table III). Social contacts and activities such as contacts
with family, friends, and neighbors; activities in groups;
physical recreation and activities; going out socially; and
going to public places were found to be adversely affected.
Patients also reported limitations with skin-exposing social
activities, such as communal swimming, sunbathing, going
to the beach, and using communal changing facilities.
Additionally, problems with sport activities, sexual activities,
and visits to the hairdresser were reported. Personal relation-
ships, such as relationships with family, relatives, and
friends, as well as the establishment of social contacts
and new friendships, appeared to be impaired. Finally, work
and career were affected, for instance, by time needed off
work, physical limitations, conflicts, loss of wages, and/or
unemployment.
Relations between age, sex, disease severity,
and quality of life
Age and sex Data on the relationship between age, sex,
and quality of life and/or disability were presented in eight
studies. Associations between age and quality of life and/or
disability were generally weak and, in some cases, incon-
sistent. Few data were statistically tested. Correlation
coefficients ranged from 0.30 to þ 0.18 (Table IV). Higher
age appeared to be associated with slightly lower levels of
physical functioning and disability and slightly higher levels
of psychological functioning and overall quality of life.
Associations between sex and quality of life and/or
disability were very weak, inconsistent, and/or absent.
Few correlation coefficients were presented, all being very
low (0.00–0.15). It appeared that sex and quality of life and/
or disability were unrelated.
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Disease severity Data on the relationship between disease
severity and quality of life and/or disability were presented
in eight studies. Although these data were not fully
consistent, disease severity appeared to be associated
with quality of life and/or disability. Coefficients expressing
the association between clinically assessed disease sever-
ity and quality of life and/or disability ranged from 0.11 to
þ0.40. Coefficients expressing the association between
patient assessed disease severity and quality of life and/or
disability ranged from 0.29 to þ0.69 (Table V). Addition-
ally, the relationships between specific disease character-
istics and quality of life and/or disability were assessed,
such as pain, pruritus, and exacerbations in emotionally
charged body regions such as head, scalp, hands, nails,
and/or genitals. Again, the presented data were not entirely
consistent, but there appeared to be a relationship between
these disease characteristics and quality of life and/or
disability. Correlation coefficients ranged from 0.28 to
þ 0.32. (Table V).
Discussion
The included studies are characterized by a high degree of
heterogeneity with respect to study design, sample char-
acteristics, disease severity, measures, and data presenta-
tion. Quality of life was assessed with a wide range of
questionnaires, each with its own conceptual framework,
scales, response format, and scoring system. Of the 14
questionnaires employed, 10 were applied only once.
Additionally, the majority of the studies suffered from one
or more methodologic weaknesses, such as the use of
small sample sizes, the use of less common and/or study-
specific measures, the absence of statistical testing, and an
Table II. SF-36: physical component summary (PCS) and mental component summary (MCS)
PCS MCS
Studya n Meanb SD p valuec Meanb SD p valuec
5 150 55.5 14.4 o 0.001 45.2 12.1 o 0.001
11 644 51.4 9.2 o 0.001 50.9 9.3 o 0.01
13 317 41.2 14.2 o 0.001 45.7 11.4 o 0.001
15 282 44.3 10.4 o 0.001 45.5 11.1 o 0.001
a5¼Fortune et al (1997); 11¼Nichol et al (1996); 13¼Rapp et al (1999); 15¼Wahl et al (1999a).
bMean scores higher than 50 indicate higher levels of quality of life than that of the general population.
cp value from two-sided t test of the difference between the mean scores of each individual study and population norm scores (mean, 50; SD, 10).
Table III. Impairments of physical, psychological, and social functioning
Physical functioning Psychological functioning Social functioning
Physical symptoms6,8,11,13 General mental health11–13 Social contacts and activities2,3,6,8,10–13
Physical functioning and/or mobility3,10–13 Emotional functioning3,6,8,10,12,13 Skin-exposing social activities2,6,8,17
Daily activities2,3,6 Body and self-image8,10 Sports2,8
Vitality11–13 Psoriasis-related concern8,10 Sexual behavior2,8
Sleep and rest3,8 Hairdressing2,6,8
Personal relationships2,8,10,17
Work and career2,3,6,8,10–13
2¼Finlay and Coles (1995); 3¼Finlay et al (1990); 6¼Gupta and Gupta (1995); 8¼Koo (1996); 10¼McKenna and Stern (1997); 11¼Nichol et al
(1996); 12¼O’Neill and Kelly (1996); 13¼Rapp et al (1999); 17¼Wall et al (1998).
Table IV. Relationship between age and quality of life and/or disability: Pearson correlation coefﬁcient, ra
DLQI PDI SF-36: PCS SF-36: MCS SIP
Age 11: N.A.(w) 3: N.A.() 11: N.A.(w) 13: 0.14 3: N.A.()
11: N.A.(w) 13: 0.30 15: 0.18
15: 0.12 15: 0.22
ar, coefficients of the magnitude of p0.3 are generally considered as low, of X0.7 as high.
N.A.: r-value not available, correlation verbally reported; N.A.(), r-value not available, correlation verbally reported as not statistically significant.
:po0.001; :po0.01; :po0.05.
DLQI and PDI scores, negative r-values and (w), higher age correlates with lower levels of disability. SF-36 PCS and MCS, positive r-values and (w),
higher age correlates with higher levels of quality of life. 3¼Finlay et al, 1990. 11¼Nichol et al, 1996. 13¼Rapp et al, 1999. 15¼Wahl et al, 1999a.
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incomplete presentation of quality-of-life data and analyses.
The high degree of heterogeneity and the methodologic
shortcomings of the included studies complicated the
comparison and synthesis of study results. The application
of more strict inclusion criteria in this study could, to some
extent, have decreased the degree of heterogeneity and the
number of these shortcomings, but would have implied a
substantially smaller number of included studies and,
thereby, a great loss and reduced generalizability of data.
The present review points to several areas for future
research. A first area of interest is the assessment of overall
quality of life. In the present review overall scores were
difficult to interpret, because of the variability of scores and
the absence of formal reference values or norm scores
(DLQI and PDI), inconsistent results (SF-36), or the absence
of formal comparisons with population norms (SIP). With
respect to the SF-36, for instance, quality of life was
significantly lower than that of the general population in one
study, but more or less equal to that of the general
population in another study. More research with the SF-36
and/or other well-established questionnaires is needed to
generate a consistent body of knowledge of overall quality
of life of patients with psoriasis. Furthermore, as we
reported in a recent review of quality-of-life questionnaires
for psoriasis research (de Korte et al, 2002) application of
both a generic and a disease- or dermatology-specific
quality-of-life questionnaire will cover the full range of
quality-of-life issues.
A second area of interest is a more detailed study of
psychological and social functioning in patients with
psoriasis. First, in four studies, it was concluded that
psoriasis affects psychological or psychosocial functioning
most. Second, relatively few data were presented on
relevant aspects, such as body and self-image, specific
emotions, concern about psoriasis, and sexual behavior.
These few data, however, do indicate that patients may
particularly suffer from embarrassment, self-consciousness,
and a negative body image. And finally, results from the
present review suggest that social activities in public
situations are more likely to be affected by psoriasis than
social activities and relationships with friends and relatives.
Future research is needed to clarify these issues.
A third area of interest is the study of the relationship
between disease severity and quality of life. First, as
reported under Materials and Methods, no clear pattern in
overall quality of life or physical, psychological, or social
functioning could be found across studies that differed in
disease severity. Most likely, this is due to the heterogeneity
of the studies. Within the eight studies presenting data on
this relationship, the association between clinically as-
sessed disease severity and quality of life was generally
weak (correlation coefficients of the magnitude of p0.3).
The association between patient-assessed disease severity
and quality of life appeared to be stronger. Second, data on
the relationship between specific psoriasis characteristics
and quality of life suggest that itch, pain, and exacerbations
in emotionally charged body areas could be relevant
predictors of quality of life. A deeper insight into these
relations is important because of conceivable conse-
quences for disease-severity measurement in quality-of-life
TableV. Relationship between disease severity and quality of life: Pearson correlation coefﬁcient, ra
DLQI PDI SF-36: PCS SF-36: MCS SIP
Clinically assessed disease severity
Body involvement (%) or number of affected sites 11. 0.26 2. 0.27 11. 0.10 11. 0.10
11. 0.27
Overall severity rating 14. 0.11 (rs)
Psoriasis Area and Severity Index 3. 0.40 (rs) 5. NA () 5. NA () 3. NA ()
Patient-assessed disease severity
Self-Administered Psoriasis Area and Severity Index 13. NA (þ ) 13. NA (þ )
Overall severity rating 14. 0.69 (rs) 15. 0.44 15. 0.29
14. 0.53
Clinically assessed disease characteristics
Exacerbation in emotionally charged body regions 15. 0.31 5. NA 5. NA
15. 0.20 15. 0.18
Pain 11. 0.30 11. 0.20 11. 0.21 11. 0.08
13. 0.28 13. NA ()
Pruritus 11. 0.32 11. 0.21 11. 0.15 11. NA ()
13. NA () 13. 0.15
ar, coefficients of the magnitude of p0.3 are generally considered as low, of X0.7 as high. rs, Spearman rank correlation coefficient.
NA, r value not available, correlation verbally reported; NA (), r value not available, correlation verbally reported as not statistically significant; NA (þ ),
r value not available, correlation verbally reported as statistically significant.
p o 0.001; p o 0.01; p o 0.05.
DLQI and PDI, positive r values, more severe psoriasis correlates with higher levels of disability.
SF-36 physical component summary score (PCS) and mental component summary score (MCS), negative r values, more severe psoriasis correlates with
lower levels of quality of life.
2¼Finlay and Coles (1995); 3¼Finlay et al (1990); 5¼Fortune et al (1997); 11¼Nichol et al (1996); 13¼Rapp et al (1999); 14¼Root et al (1994);
15¼Wahl et al (1999a).
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research. For instance, the well-established Psoriasis Area
and Severity Index does not include the assessment of
these specific characteristics.
A fourth area of interest concerns the relationship
between psychological variables and quality of life. In this
review, we were unable to combine data on this relation-
ship, owing to the very small number of data presented in
the included studies. Nevertheless, because demographic
and clinical factors explain only part of the variability in
quality of life, it was suggested in several studies that
psychological and social factors could be important
predictors of quality of life. Susceptibility to stress, the ability
to cope with impairments, and the availability of social
support may indeed affect the quality of life of patients with
psoriasis and may even explain a large part of the variability
between patients. Research in this field may contribute to a
better understanding of this relationship.
Additionally, future studies are needed to assess the
effects of dermatologic treatment on quality of life. In this
review, the objective of five of the included studies was to
assess the outcome of dermatologic therapies. The focus
of most studies was limited to a demonstration of positive
effects of dermatologic treatment—topical therapy, photo-
therapy, systemic therapy, and inpatient management—on
overall quality of life. Future outcome studies may provide a
clearer understanding of the short- and long-term effects of
dermatologic treatment on overall quality of life, as well as
on (aspects of) physical, psychological, and social function-
ing. Outcome studies may also provide an insight in the
contribution of adjunct interventions, such as training in
disease and stress management and psychological support.
Finally, because quality-of-life research in chronic (skin)
disease is expanding, it would be interesting to conduct a
systematic review of quality-of-life studies over a subse-
quent period of time and to compare these results with the
results of this review.
Materials and Methods
Data sources Five computerized bibliographical databases were
screened for publications: CINAHL (CINAHL Information Systems,
Glendale, CA, January 1982 to April 2000), Current Contents
(Institute for Scientific Information, Philadelphia, PA, January 1997
to April 2000), EMBASE (Elsevier Science Publishers, Amsterdam,
the Netherlands, January 1980 to April 2000), MEDLINE (National
Library of Medicine, Bethesda, MD, January 1966 to April 2000),
and PsycINFO (American Psychological Association, Washington,
DC, January 1974 to April 2000). The search was restricted to
publications in English. Key words were established by means of a
pilot search. The key word ‘‘psoriasis’’ was used in combination
with ‘‘quality of life’’ (including ‘‘health-related quality of life’’ and
‘‘health status’’ as equivalents). Because of incidental use of
related concepts in the publications, the search was expanded by
the key words ‘‘handicap’’ and ‘‘disability’’ as equivalents of
‘‘quality of life,’’ despite their different meaning.
Study selection: inclusion and exclusion criteria We included
studies reporting data on quality of life in patients with psoriasis,
generated by means of quality-of-life questionnaires and/or
questionnaires on related concepts, such as disability, handicap,
and stress. Excluded were studies restricted to psoriasis arthritis,
psoriasis of the nails, and scalp psoriasis and studies restricted to
a single aspect of quality of life. Two investigators independently
assessed quality-of-life studies for inclusion. In case of disagree-
ment, all arguments were discussed, whereupon consensus was
reached. (The studies are represented in the tables by Arabic
numerals.)
Data extraction We extracted data on: (1) the study objectives,
study design, sample characteristics, disease severity, and quality-
of-life measures; (2) overall quality of life, physical functioning,
psychological functioning, social functioning, and/or well-being;
and (3) the relation between demographic and clinical variables
and quality of life.
Data synthesis First, we assembled data on study objectives,
study designs, sample characteristics, disease severity, and
quality-of-life measures (Table I). We then grouped studies
according to the degree of disease severity of the samples: three
subgroups of predominantly mild, mild to moderate, and severe
psoriasis could be composed. The quality-of-life results of these
subgroups were compared. No clear pattern in overall quality of life
or physical, psychological, or social functioning emerged. We
therefore decided to combine all extracted quality-of-life data into
one synthesis. The application of quality-of-life results from
outcome studies was restricted to baseline data.
Next, a synthesis of overall quality-of-life results was made. A
comparison of mean overall quality-of-life scores was possible with
respect to the Dermatology Life Quality Index (DLQI), Psoriasis
Disability Index (PDI), Sickness Impact Profile (SIP), and the MOS
36-Item Short-Form Health Survey (SF-36) questionnaire (mean,
standard deviation, and level of significance) (Table II). Owing to
the heterogeneity of questionnaires, a comparison of scores
on physical, psychological, and/or physical functioning was not
possible. Therefore, a descriptive overview of physical, psycholo-
gical, and social impairments was made. Impaired aspects of
functioning reported in more than one study were included in this
overview (Table III).
Finally, a synthesis of extracted data on the relation between
demographic and clinical variables and quality of life was made. A
uniform presentation of data (correlation coefficient, level of
significance) was possible only for age (Table IV) and disease
severity (Table V). With respect to disease severity, a distinction
was made between clinically assessed and patient-assessed
disease severity and specific disease characteristics (exacerba-
tions in emotionally charged body regions, pain, and pruritus).
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